Table 3 Response assessment in ELN 2017.
Overall (n = 175) | ELN2017 | pval | |||
|---|---|---|---|---|---|
Favourable risk(n = 82) | Intermediate risk(n = 65) | Adverse risk (n = 28) | |||
After 1 cycle of induction therapy | |||||
ORR | 82.8% (145) | 95.1% (78) | 76.9% (50) | 60.7% (17) | p = 0.024 |
CRc | 81.1% (142) | 93.9% (77) | 74.8% (48) | 60.7% (17) | |
CR | 77.1%(135) | 91.5% (75) | 67.7% (44) | 57.1% (16) | |
CRi | 4.0% (7) | 2.4% (2) | 6.2% (4) | 3.6% (1) | |
PR | 1.7% (3) | 1.2% (1) | 3.1% (2) | 0 | |
NR | 11.4% (20) | 2.4% (2) | 18.4% (12) | 21.4% (6) | p < 0.001 |
After 2 cycle of induction therapy | |||||
ORR | 90.2% (158) | 96.3% (79) | 89.2% (58) | 75% (21) | p = 0.0046 |
CRc | 89.1% (156) | 96.3% (79) | 87.7% (57) | 71.4% (20) | |
CR | 84.6% (148) | 93.9% (77) | 81.5% (53) | 64.3% (18) | |
CRi | 4.6% (8) | 2.4% (2) | 6.2% (4) | 7.1% (2) | |
PR | 1.1% (2) | 0 | 1.5% (1) | 3.6% (1) | |
NR | 4% (7) | 1.2% (1) | 6.2% (4) | 7.1% (2) | |
Early death rate | 5.7% (10) | 2.4% (2) | 4.6% (3) | 17.9% (5) | |
Re-induction therapy regimen of NR patients | |||||
Venetoclax + azacitidine | 9 | 1 | 2 | ||
Venetoclax + azacitidine + homoharringtonine | 3 | 0 | 2 | ||
FLAG/CLAG | 4 | 1 | 2 | ||
CAG | 2 | 0 | 0 | ||
HA | 2 | 0 | 0 | ||
Allo-HSCT | 20% (35) | 14.6% (12) | 21.5% (14) | 32.1% (9) | p = 0.083 |
MRD- after induction in CR patients | 65.5% (97) | 70.0% (54) | 62.3% (33) | 56% (10) | p = 0.41 |
Median duration of MRD- status (IQR), days | 244 (60–662) | 288 (130–693) | 205 (33–614) | 291 (0–697) | |
Median OS (IQR), days | 454 (220–871) | 486 (195–863) | 482 (231–964) | 398 (146–627) | |
